Test Price
1,500 AED✅ Home Collection Available
FIP1L1-PDGFRA Gene Rearrangement Detection Test in the UAE | AED 1500 | DHA Licensed
Executive Summary & Core Metrics
Our ISO 9001:2015 accredited laboratory ensures 99.9% diagnostic sensitivity and specificity for FIP1L1-PDGFRA fusion detection, the hallmark of imatinib-responsive chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome. Sample collection is performed in an accredited hospital facility only; mobile phlebotomy is not available for this test due to invasive bone marrow sample requirements. Complimentary post-test telephonic consultation with a consultant medical geneticist is provided. Direct insurance billing verification via WhatsApp.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. ISO Certified Cold‑Chain Transport for specimen stability.
- Clinical Guidance: Complimentary Post‑Test Telephonic Interpretation by a Specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This molecular test detects the FIP1L1‑PDGFRA fusion gene using qualitative reverse transcription polymerase chain reaction (RT-PCR), the gold standard for diagnosing chronic eosinophilic leukemia (CEL) and guiding imatinib therapy. The test identifies the precise rearrangement that drives autonomous eosinophil production, enabling targeted treatment and monitoring.
| Feature | Our Test (PCR‑based) | Closest Alternative (FISH/Karyotype) |
|---|---|---|
| Precision | 99.9% Sensitivity & Specificity | ~85‑92% Sensitivity, requires metaphase cells |
| Methodology | Qualitative RT‑PCR (ISO 9001:2015) | Fluorescence in‑situ Hybridization / Karyotype |
| Turnaround | 12 days from sample receipt (Monday by 11 AM cutoff) | 14‑21 days, often requiring culture |
| Sample | Hospital extraction: 4 mL whole blood (EDTA) or bone marrow aspirate; strictly refrigerated transport | Bone marrow aspirate or heparinised blood |
Physician Insight & Safety Protocols
“This test identifies the FIP1L1‑PDGFRA fusion, a decisive driver in hypereosinophilic syndrome and chronic eosinophilic leukemia. Clinical correlation with absolute eosinophil count, organ function tests, and imaging is vital; a negative result does not rule out other eosinophilic disorders that may require different management strategies. The fusion predicts excellent response to imatinib, but therapy must be initiated and monitored by a hematologist.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
⚠️ Medication Safety Notice
Do not discontinue prescribed corticosteroid or imatinib therapy without consulting your doctor. Abrupt cessation may cause rapid eosinophil rise and organ damage. Always inform the attending physician of all current medications before sample collection.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Uncontrolled active bleeding or platelet count <20×10⁹/L prior to bone marrow procedure.
- Haemoglobin <8 g/dL requiring pre‑test transfusion.
- Inability to provide mandatory Genomics Clinical Information Requisition Form (Form 20) – signed by patient or legal guardian.
- Minors without guardian consent – legal guardian must accompany for consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- ER Red Flags: Acute vision loss, confusion, severe bone pain, or new‑onset breathlessness; seek immediate emergency care before test scheduling.
Patient FAQ & Clinical Guidance
1. What does a positive FIP1L1‑PDGFRA result mean?
A confirmed FIP1L1‑PDGFRA rearrangement indicates chronic eosinophilic leukemia (CEL) or hypereosinophilic syndrome that is likely responsive to imatinib therapy. The finding guides targeted treatment to rapidly reduce eosinophil counts and prevent organ damage. Discuss the result with a hematologist to establish a complete care plan.
2. What sample is required, and how should it be handled?
A 4 mL whole blood sample in an EDTA tube or a bone marrow aspirate is required. The sample must be kept refrigerated (2–8°C) and never frozen. Freezing destroys nucleic acids and invalidates the test. Collection is performed only in a hospital setting; our logistics team arranges temperature-controlled courier from the facility to the laboratory.
3. How should I prepare for the test?
Complete the mandatory Genomics Clinical Information Requisition Form (Form 20) accurately. Inform your physician of all medications, especially imatinib or corticosteroids. Fasting is not required for blood collection, but if a bone marrow aspirate is planned, your doctor may provide specific instructions. Ensure you have valid identification and insurance details.
4. How long does it take to get results?
Results are typically available 12 days from sample receipt at our laboratory, provided the sample arrives before the Monday 11 AM cutoff. Reports are delivered electronically and via courier, followed by a complimentary telephonic interpretation from our genetic specialist.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and complies with all applicable UAE data protection and health information laws. All patient data is handled in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical procedures and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory processing follows ISO 9001:2015 quality standards.
Physical Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. For data privacy inquiries, contact our Data Protection Officer.
Clinical & Logistical Metadata
| Test Name | FIP1L1-PDGFRA Gene Rearrangement Detection |
| Price (AED) | 1,500 |
| Turnaround Time | 12 days from sample receipt (Monday 11 AM cutoff) |
| Sample Type / Matrix | Whole blood (4 mL, EDTA) or bone marrow aspirate; strictly refrigerated transport. Hospital extraction only. |
| Methodology Used | Qualitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) – ISO 9001:2015 |
| ICD-10-CM Code | D47.5 (Chronic eosinophilic leukemia / Hypereosinophilic syndrome) |
| LOINC Code | 38288-2 (FIP1L1/PDGFRA rearrangement [Presence] in Blood or Tissue by PCR) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians